Company / PP&E (Net)
Esperion Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$338.0K
FY2025
5-year range
$0 / $664.0K
FY2021-FY2025
Trend
+33.1%
vs FY2024
Sector context
#174 of 193
Health Care
What the data says
Among 193 Health Care companies, Esperion Therapeutics, Inc. is in the bottom 10% for pp&e (net). PP&E (Net) has fluctuated over the past 10 years, ranging from $0 in FY2023 to $1M in FY2020.
Based on SEC 10-K filings.
$338,000 in FY2025 with a 5-year CAGR of -23.3%.
Improved from $0 to $338,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +27.3%
- 5-Year CAGR
- -23.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 193This company $338.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -23.3%, indicating a declining trend.
- In FY2025, pp&e (net) increased 33.1% year-over-year.
- Ranks #174 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $338.0K | +33.1% |
| FY2024 | $254.0K | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $164.0K | -75.3% |
| FY2021 | $664.0K | -48.0% |
| FY2020 | $1.3M | +11.4% |
| FY2019 | $1.1M | +120.2% |
| FY2018 | $520.0K | +19.5% |
| FY2017 | $435.0K | -35.5% |
| FY2016 | $674.0K | -16.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026